| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colonic Neoplasms | 37 | 2020 | 589 | 2.810 |
Why?
|
| Transcranial Direct Current Stimulation | 6 | 2022 | 16 | 2.600 |
Why?
|
| Adenocarcinoma | 34 | 2022 | 1215 | 2.490 |
Why?
|
| Semantics | 9 | 2025 | 55 | 2.470 |
Why?
|
| Veterans | 8 | 2023 | 100 | 2.220 |
Why?
|
| Mental Recall | 7 | 2021 | 173 | 2.190 |
Why?
|
| Evoked Potentials | 8 | 2020 | 202 | 2.120 |
Why?
|
| Cognitive Dysfunction | 9 | 2024 | 192 | 2.000 |
Why?
|
| Barrett Esophagus | 17 | 2021 | 94 | 1.970 |
Why?
|
| Liver | 31 | 2022 | 1238 | 1.880 |
Why?
|
| Combat Disorders | 3 | 2023 | 7 | 1.840 |
Why?
|
| Brain Injuries, Traumatic | 7 | 2024 | 125 | 1.830 |
Why?
|
| Adenoma | 11 | 2023 | 260 | 1.680 |
Why?
|
| Humans | 276 | 2025 | 96127 | 1.670 |
Why?
|
| Immunohistochemistry | 43 | 2024 | 1829 | 1.640 |
Why?
|
| Aging | 6 | 2024 | 766 | 1.590 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2023 | 125 | 1.580 |
Why?
|
| Male | 191 | 2025 | 45870 | 1.550 |
Why?
|
| Liver Neoplasms | 15 | 2020 | 793 | 1.530 |
Why?
|
| Gastritis | 6 | 2023 | 39 | 1.480 |
Why?
|
| Middle Aged | 134 | 2025 | 28363 | 1.440 |
Why?
|
| Stomach Neoplasms | 11 | 2020 | 310 | 1.370 |
Why?
|
| Female | 167 | 2025 | 50063 | 1.360 |
Why?
|
| Carcinoma, Hepatocellular | 11 | 2020 | 426 | 1.340 |
Why?
|
| Neuropsychological Tests | 13 | 2024 | 549 | 1.330 |
Why?
|
| Colorectal Neoplasms | 21 | 2023 | 1069 | 1.330 |
Why?
|
| Liver Cirrhosis | 12 | 2021 | 276 | 1.310 |
Why?
|
| Biopsy | 32 | 2025 | 1220 | 1.270 |
Why?
|
| Biomarkers, Tumor | 18 | 2020 | 1665 | 1.250 |
Why?
|
| Liver Diseases | 8 | 2018 | 249 | 1.240 |
Why?
|
| Colitis, Ulcerative | 17 | 2023 | 801 | 1.230 |
Why?
|
| Adult | 101 | 2025 | 28718 | 1.220 |
Why?
|
| Brain | 12 | 2020 | 2482 | 1.220 |
Why?
|
| Colitis | 13 | 2020 | 262 | 1.210 |
Why?
|
| Aged | 87 | 2025 | 20964 | 1.170 |
Why?
|
| Crohn Disease | 9 | 2023 | 806 | 1.160 |
Why?
|
| Hypertension, Portal | 2 | 2023 | 47 | 1.130 |
Why?
|
| Cognition | 7 | 2020 | 635 | 1.100 |
Why?
|
| Pattern Recognition, Visual | 3 | 2020 | 162 | 1.080 |
Why?
|
| Aged, 80 and over | 45 | 2024 | 7232 | 1.070 |
Why?
|
| Esophageal Neoplasms | 15 | 2020 | 346 | 1.030 |
Why?
|
| Gastric Mucosa | 6 | 2019 | 70 | 1.030 |
Why?
|
| Precancerous Conditions | 11 | 2016 | 206 | 0.980 |
Why?
|
| Liver Transplantation | 22 | 2024 | 1201 | 0.950 |
Why?
|
| Verbal Behavior | 1 | 2025 | 33 | 0.920 |
Why?
|
| Cues | 2 | 2025 | 189 | 0.920 |
Why?
|
| Fatty Liver | 6 | 2021 | 108 | 0.900 |
Why?
|
| Chronic Traumatic Encephalopathy | 2 | 2021 | 5 | 0.880 |
Why?
|
| Gastritis, Atrophic | 1 | 2023 | 4 | 0.830 |
Why?
|
| Environmental Monitoring | 2 | 2023 | 89 | 0.830 |
Why?
|
| Intelligence | 1 | 2024 | 73 | 0.830 |
Why?
|
| Mexican Americans | 1 | 2024 | 70 | 0.830 |
Why?
|
| Educational Status | 2 | 2024 | 202 | 0.830 |
Why?
|
| Young Adult | 28 | 2025 | 7025 | 0.820 |
Why?
|
| Cerebral Cortex | 2 | 2020 | 615 | 0.810 |
Why?
|
| Escherichia coli | 2 | 2023 | 627 | 0.810 |
Why?
|
| Prefrontal Cortex | 4 | 2021 | 150 | 0.810 |
Why?
|
| Football | 4 | 2023 | 47 | 0.810 |
Why?
|
| Brain Mapping | 9 | 2019 | 594 | 0.800 |
Why?
|
| Electroencephalography | 9 | 2022 | 824 | 0.790 |
Why?
|
| Persian Gulf Syndrome | 4 | 2018 | 5 | 0.780 |
Why?
|
| Hepatocytes | 5 | 2010 | 132 | 0.770 |
Why?
|
| Contractile Proteins | 2 | 2020 | 57 | 0.770 |
Why?
|
| Endoscopic Mucosal Resection | 5 | 2022 | 28 | 0.770 |
Why?
|
| Reading | 2 | 2020 | 33 | 0.760 |
Why?
|
| Colonic Polyps | 5 | 2023 | 137 | 0.760 |
Why?
|
| Speech Perception | 2 | 2020 | 74 | 0.740 |
Why?
|
| Intestinal Mucosa | 17 | 2023 | 825 | 0.740 |
Why?
|
| Colon | 16 | 2018 | 541 | 0.730 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2023 | 40 | 0.730 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2020 | 190 | 0.730 |
Why?
|
| DNA Mutational Analysis | 5 | 2019 | 547 | 0.690 |
Why?
|
| Cognition Disorders | 4 | 2015 | 244 | 0.690 |
Why?
|
| Executive Function | 4 | 2023 | 106 | 0.690 |
Why?
|
| Anemia, Sickle Cell | 1 | 2023 | 150 | 0.690 |
Why?
|
| Retirement | 4 | 2023 | 15 | 0.680 |
Why?
|
| Reaction Time | 8 | 2025 | 323 | 0.680 |
Why?
|
| Chemical and Drug Induced Liver Injury | 6 | 2020 | 67 | 0.680 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 4 | 2019 | 187 | 0.670 |
Why?
|
| Cholangiocarcinoma | 3 | 2020 | 80 | 0.660 |
Why?
|
| Depression | 3 | 2016 | 560 | 0.660 |
Why?
|
| Anti-Bacterial Agents | 7 | 2025 | 847 | 0.650 |
Why?
|
| Gastrointestinal Tract | 3 | 2021 | 197 | 0.640 |
Why?
|
| Motor Cortex | 1 | 2022 | 215 | 0.640 |
Why?
|
| Azithromycin | 4 | 2025 | 17 | 0.630 |
Why?
|
| Psychomotor Performance | 2 | 2020 | 505 | 0.630 |
Why?
|
| Diagnosis, Differential | 19 | 2024 | 1619 | 0.620 |
Why?
|
| Inflammatory Bowel Diseases | 6 | 2021 | 647 | 0.620 |
Why?
|
| Bile Ducts, Intrahepatic | 4 | 2014 | 68 | 0.620 |
Why?
|
| Azoxymethane | 16 | 2019 | 84 | 0.610 |
Why?
|
| Graft Rejection | 19 | 2024 | 1126 | 0.610 |
Why?
|
| Adolescent | 26 | 2025 | 9896 | 0.600 |
Why?
|
| Pancreatic Neoplasms | 9 | 2022 | 725 | 0.600 |
Why?
|
| Immunosuppressive Agents | 12 | 2020 | 995 | 0.600 |
Why?
|
| Hyphema | 1 | 2018 | 1 | 0.590 |
Why?
|
| Posterior Capsular Rupture, Ocular | 1 | 2018 | 1 | 0.590 |
Why?
|
| Silicone Elastomers | 1 | 2018 | 8 | 0.590 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2018 | 11 | 0.590 |
Why?
|
| Paracentesis | 1 | 2018 | 10 | 0.590 |
Why?
|
| Cholangitis, Sclerosing | 3 | 2017 | 54 | 0.580 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2018 | 19 | 0.580 |
Why?
|
| ErbB Receptors | 10 | 2018 | 513 | 0.580 |
Why?
|
| Cataract Extraction | 1 | 2018 | 32 | 0.580 |
Why?
|
| Eye Injuries | 1 | 2018 | 15 | 0.580 |
Why?
|
| Therapeutic Irrigation | 1 | 2018 | 66 | 0.580 |
Why?
|
| Uveitis | 1 | 2018 | 35 | 0.580 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2018 | 143 | 0.570 |
Why?
|
| Gene Expression Regulation, Neoplastic | 16 | 2020 | 1351 | 0.550 |
Why?
|
| Treatment Outcome | 31 | 2023 | 9173 | 0.550 |
Why?
|
| Hepatic Duct, Common | 1 | 2017 | 10 | 0.540 |
Why?
|
| Dementia | 3 | 2024 | 218 | 0.540 |
Why?
|
| Athletes | 3 | 2016 | 58 | 0.530 |
Why?
|
| Retrospective Studies | 41 | 2025 | 10286 | 0.510 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 539 | 0.500 |
Why?
|
| Goblet Cells | 2 | 2014 | 20 | 0.490 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2016 | 24 | 0.480 |
Why?
|
| Amnesia | 1 | 2016 | 15 | 0.480 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 484 | 0.480 |
Why?
|
| Brain Concussion | 4 | 2022 | 88 | 0.470 |
Why?
|
| Hepatitis | 3 | 2023 | 36 | 0.450 |
Why?
|
| Biomarkers | 8 | 2022 | 1933 | 0.450 |
Why?
|
| Bile Duct Diseases | 1 | 2014 | 23 | 0.450 |
Why?
|
| SOX9 Transcription Factor | 1 | 2014 | 28 | 0.450 |
Why?
|
| Visual Perception | 2 | 2015 | 339 | 0.440 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 2473 | 0.440 |
Why?
|
| Carcinogenesis | 5 | 2019 | 237 | 0.440 |
Why?
|
| Alzheimer Disease | 4 | 2022 | 606 | 0.440 |
Why?
|
| Depressive Disorder | 1 | 2015 | 226 | 0.440 |
Why?
|
| Bile Duct Neoplasms | 4 | 2020 | 91 | 0.440 |
Why?
|
| Inflammation | 9 | 2023 | 1068 | 0.430 |
Why?
|
| Gastrointestinal Diseases | 3 | 2024 | 154 | 0.430 |
Why?
|
| MicroRNAs | 5 | 2020 | 592 | 0.430 |
Why?
|
| West Nile Fever | 1 | 2014 | 22 | 0.430 |
Why?
|
| Association Learning | 1 | 2014 | 38 | 0.420 |
Why?
|
| Prognosis | 15 | 2023 | 4033 | 0.420 |
Why?
|
| Trachoma | 3 | 2019 | 3 | 0.420 |
Why?
|
| Mutation | 10 | 2019 | 4374 | 0.410 |
Why?
|
| Case-Control Studies | 14 | 2021 | 1958 | 0.410 |
Why?
|
| Disease Progression | 14 | 2024 | 1568 | 0.400 |
Why?
|
| Predictive Value of Tests | 10 | 2024 | 1807 | 0.400 |
Why?
|
| Esophagoscopy | 6 | 2012 | 91 | 0.400 |
Why?
|
| Hepatic Veno-Occlusive Disease | 3 | 2012 | 19 | 0.400 |
Why?
|
| Colonoscopy | 7 | 2023 | 304 | 0.390 |
Why?
|
| Stromal Cells | 4 | 2020 | 154 | 0.390 |
Why?
|
| Pathologists | 2 | 2025 | 40 | 0.390 |
Why?
|
| Hemochromatosis | 2 | 2009 | 12 | 0.380 |
Why?
|
| Psychomotor Agitation | 1 | 2012 | 31 | 0.380 |
Why?
|
| Language Tests | 2 | 2016 | 39 | 0.380 |
Why?
|
| Carcinoma | 5 | 2023 | 449 | 0.380 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 172 | 0.380 |
Why?
|
| Cell Transformation, Neoplastic | 11 | 2014 | 466 | 0.380 |
Why?
|
| Severity of Illness Index | 14 | 2020 | 1981 | 0.380 |
Why?
|
| Cadherins | 6 | 2009 | 180 | 0.370 |
Why?
|
| White Matter | 4 | 2017 | 96 | 0.370 |
Why?
|
| United States | 16 | 2021 | 7767 | 0.370 |
Why?
|
| Evoked Potentials, Visual | 1 | 2012 | 90 | 0.370 |
Why?
|
| Memory Disorders | 2 | 2015 | 72 | 0.360 |
Why?
|
| Glutamate-Ammonia Ligase | 2 | 2023 | 12 | 0.360 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 79 | 0.360 |
Why?
|
| Postoperative Complications | 8 | 2018 | 2591 | 0.350 |
Why?
|
| Follow-Up Studies | 17 | 2023 | 3927 | 0.350 |
Why?
|
| Microdissection | 1 | 2011 | 18 | 0.340 |
Why?
|
| Reproducibility of Results | 14 | 2023 | 2883 | 0.340 |
Why?
|
| Mass Drug Administration | 3 | 2019 | 4 | 0.340 |
Why?
|
| Disease Models, Animal | 14 | 2019 | 2551 | 0.340 |
Why?
|
| Keratin-7 | 1 | 2010 | 10 | 0.340 |
Why?
|
| Lasers | 1 | 2011 | 102 | 0.330 |
Why?
|
| Histoplasmosis | 2 | 2009 | 28 | 0.330 |
Why?
|
| Down-Regulation | 9 | 2020 | 527 | 0.330 |
Why?
|
| Arginase | 1 | 2010 | 16 | 0.330 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2010 | 17 | 0.330 |
Why?
|
| Hemostasis, Surgical | 1 | 2010 | 25 | 0.330 |
Why?
|
| Cholestasis | 1 | 2010 | 44 | 0.330 |
Why?
|
| Gastric Antral Vascular Ectasia | 1 | 2010 | 1 | 0.330 |
Why?
|
| Opportunistic Infections | 2 | 2009 | 60 | 0.320 |
Why?
|
| Matrix Metalloproteinases | 2 | 2009 | 30 | 0.320 |
Why?
|
| Adenomatous Polyposis Coli Protein | 4 | 2019 | 42 | 0.320 |
Why?
|
| Hemostatics | 1 | 2010 | 61 | 0.320 |
Why?
|
| Recurrence | 5 | 2023 | 1218 | 0.320 |
Why?
|
| Intestine, Small | 9 | 2025 | 310 | 0.320 |
Why?
|
| Cytoskeletal Proteins | 5 | 2008 | 227 | 0.320 |
Why?
|
| Mice | 41 | 2021 | 12562 | 0.310 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2010 | 50 | 0.310 |
Why?
|
| Tranexamic Acid | 1 | 2010 | 43 | 0.310 |
Why?
|
| Cyclin D1 | 7 | 2007 | 85 | 0.310 |
Why?
|
| Adenomatous Polyposis Coli | 2 | 2025 | 45 | 0.310 |
Why?
|
| Animals | 59 | 2021 | 28945 | 0.300 |
Why?
|
| Sensitivity and Specificity | 10 | 2016 | 2040 | 0.300 |
Why?
|
| Vascular Surgical Procedures | 1 | 2010 | 152 | 0.300 |
Why?
|
| Antigens, CD | 3 | 2010 | 482 | 0.300 |
Why?
|
| Microscopy, Confocal | 5 | 2018 | 286 | 0.300 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2019 | 3651 | 0.300 |
Why?
|
| Hepatitis C | 5 | 2009 | 185 | 0.300 |
Why?
|
| Child Mortality | 2 | 2019 | 9 | 0.300 |
Why?
|
| Gene Expression Profiling | 6 | 2017 | 1534 | 0.290 |
Why?
|
| Hematoma | 1 | 2009 | 109 | 0.290 |
Why?
|
| Trans-Activators | 5 | 2005 | 447 | 0.290 |
Why?
|
| Toxocariasis | 1 | 2008 | 2 | 0.290 |
Why?
|
| Multiple Sclerosis | 3 | 2018 | 263 | 0.280 |
Why?
|
| Pandemics | 4 | 2023 | 880 | 0.280 |
Why?
|
| Alanine Transaminase | 4 | 2013 | 73 | 0.280 |
Why?
|
| Neuroendocrine Tumors | 2 | 2022 | 136 | 0.270 |
Why?
|
| Transplantation, Homologous | 13 | 2014 | 1023 | 0.270 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2009 | 187 | 0.270 |
Why?
|
| Gene Amplification | 3 | 2018 | 143 | 0.270 |
Why?
|
| beta Catenin | 9 | 2016 | 267 | 0.270 |
Why?
|
| Mitochondrial Proteins | 3 | 2021 | 129 | 0.260 |
Why?
|
| Colectomy | 4 | 2018 | 192 | 0.260 |
Why?
|
| Learning | 2 | 2025 | 305 | 0.260 |
Why?
|
| Remission Induction | 6 | 2020 | 769 | 0.260 |
Why?
|
| Renin-Angiotensin System | 3 | 2018 | 84 | 0.260 |
Why?
|
| Observer Variation | 5 | 2021 | 626 | 0.260 |
Why?
|
| Longitudinal Studies | 4 | 2024 | 1175 | 0.260 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2012 | 713 | 0.260 |
Why?
|
| Genetic Therapy | 1 | 2009 | 382 | 0.250 |
Why?
|
| Water Microbiology | 2 | 2023 | 16 | 0.250 |
Why?
|
| Memory | 2 | 2020 | 229 | 0.250 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2006 | 4 | 0.250 |
Why?
|
| Neoplasm Grading | 5 | 2019 | 404 | 0.250 |
Why?
|
| Infant | 13 | 2025 | 3363 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2020 | 1020 | 0.240 |
Why?
|
| Stomach | 2 | 2021 | 115 | 0.240 |
Why?
|
| Conservation of Natural Resources | 3 | 2018 | 98 | 0.230 |
Why?
|
| Plant Extracts | 3 | 2016 | 248 | 0.230 |
Why?
|
| Membrane Proteins | 6 | 2021 | 1276 | 0.230 |
Why?
|
| Child | 15 | 2024 | 7626 | 0.230 |
Why?
|
| Names | 1 | 2025 | 11 | 0.230 |
Why?
|
| Intestinal Polyposis | 1 | 2025 | 5 | 0.230 |
Why?
|
| Esophagectomy | 5 | 2022 | 92 | 0.230 |
Why?
|
| Liver Failure | 2 | 2003 | 69 | 0.230 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2025 | 6 | 0.230 |
Why?
|
| Comorbidity | 5 | 2016 | 1011 | 0.230 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2019 | 180 | 0.230 |
Why?
|
| Principal Component Analysis | 3 | 2015 | 168 | 0.230 |
Why?
|
| Child, Preschool | 13 | 2024 | 3974 | 0.230 |
Why?
|
| Soft Tissue Infections | 1 | 2025 | 27 | 0.230 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2016 | 17 | 0.230 |
Why?
|
| Busulfan | 3 | 2012 | 43 | 0.230 |
Why?
|
| Collagen | 2 | 2022 | 307 | 0.230 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2015 | 65 | 0.220 |
Why?
|
| Antiviral Agents | 4 | 2017 | 504 | 0.220 |
Why?
|
| Thioguanine | 1 | 2004 | 17 | 0.220 |
Why?
|
| Feces | 2 | 2023 | 360 | 0.220 |
Why?
|
| Rituximab | 1 | 2025 | 133 | 0.220 |
Why?
|
| Staining and Labeling | 3 | 2017 | 173 | 0.220 |
Why?
|
| Cross-Sectional Studies | 5 | 2019 | 1874 | 0.220 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2025 | 84 | 0.220 |
Why?
|
| Intestinal Diseases | 1 | 2025 | 85 | 0.210 |
Why?
|
| Caveolins | 1 | 2004 | 4 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 6 | 2019 | 590 | 0.210 |
Why?
|
| Antigens, Bacterial | 2 | 2019 | 138 | 0.210 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2024 | 24 | 0.210 |
Why?
|
| Thrombospondin 1 | 1 | 2004 | 22 | 0.210 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2016 | 161 | 0.210 |
Why?
|
| Genes, APC | 2 | 2019 | 27 | 0.210 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2024 | 29 | 0.210 |
Why?
|
| Apoptosis | 8 | 2019 | 1763 | 0.210 |
Why?
|
| Isoantibodies | 2 | 2016 | 127 | 0.210 |
Why?
|
| Caveolin 1 | 3 | 2017 | 25 | 0.210 |
Why?
|
| Time Factors | 16 | 2019 | 5585 | 0.210 |
Why?
|
| Exodeoxyribonucleases | 1 | 2023 | 17 | 0.210 |
Why?
|
| Cohort Studies | 11 | 2024 | 3107 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2007 | 152 | 0.210 |
Why?
|
| Water Pollution | 1 | 2023 | 10 | 0.210 |
Why?
|
| Fresh Water | 1 | 2023 | 24 | 0.210 |
Why?
|
| von Willebrand Factor | 1 | 2023 | 40 | 0.200 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 22 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 2005 | 67 | 0.200 |
Why?
|
| Biology | 1 | 2023 | 52 | 0.200 |
Why?
|
| Asparaginase | 1 | 2003 | 35 | 0.200 |
Why?
|
| Hepatitis, Autoimmune | 5 | 2008 | 20 | 0.200 |
Why?
|
| Sewage | 1 | 2023 | 4 | 0.200 |
Why?
|
| Osteochondrodysplasias | 1 | 2003 | 11 | 0.200 |
Why?
|
| Receptors, Calcitriol | 3 | 2019 | 131 | 0.200 |
Why?
|
| Allografts | 3 | 2024 | 207 | 0.200 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2015 | 1323 | 0.200 |
Why?
|
| Sigmoid Diseases | 1 | 2003 | 4 | 0.200 |
Why?
|
| Elephants | 2 | 2015 | 18 | 0.200 |
Why?
|
| Helicobacter Infections | 2 | 2021 | 38 | 0.200 |
Why?
|
| Helicobacter pylori | 2 | 2021 | 38 | 0.200 |
Why?
|
| Carcinoma, Neuroendocrine | 3 | 2012 | 40 | 0.200 |
Why?
|
| Histiocytosis, Sinus | 1 | 2003 | 17 | 0.200 |
Why?
|
| Hemodynamics | 2 | 2018 | 781 | 0.200 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2004 | 244 | 0.200 |
Why?
|
| Doxycycline | 2 | 2013 | 37 | 0.200 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2020 | 115 | 0.190 |
Why?
|
| Heart Failure | 2 | 2010 | 1422 | 0.190 |
Why?
|
| Photic Stimulation | 3 | 2014 | 514 | 0.190 |
Why?
|
| Thorax | 1 | 2003 | 80 | 0.190 |
Why?
|
| Prevalence | 4 | 2023 | 1349 | 0.190 |
Why?
|
| Islets of Langerhans | 2 | 2021 | 559 | 0.190 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2013 | 62 | 0.190 |
Why?
|
| Hyperammonemia | 2 | 2020 | 14 | 0.190 |
Why?
|
| Dilatation, Pathologic | 2 | 2014 | 55 | 0.190 |
Why?
|
| Mice, Inbred C57BL | 19 | 2019 | 3490 | 0.190 |
Why?
|
| Lymphocytosis | 1 | 2022 | 12 | 0.190 |
Why?
|
| Hepatitis C, Chronic | 2 | 2017 | 96 | 0.190 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2014 | 133 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 10 | 2011 | 1431 | 0.190 |
Why?
|
| Health Personnel | 1 | 2025 | 241 | 0.190 |
Why?
|
| Glycogen Storage Disease Type IV | 1 | 2002 | 1 | 0.190 |
Why?
|
| Hippocampus | 3 | 2019 | 459 | 0.190 |
Why?
|
| Vitamin D | 2 | 2019 | 273 | 0.190 |
Why?
|
| Risk Factors | 12 | 2023 | 5960 | 0.180 |
Why?
|
| Weight Loss | 1 | 2004 | 240 | 0.180 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2016 | 118 | 0.180 |
Why?
|
| Fibrosis | 3 | 2021 | 246 | 0.180 |
Why?
|
| Losartan | 2 | 2019 | 30 | 0.180 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2015 | 82 | 0.180 |
Why?
|
| Tissue Array Analysis | 3 | 2011 | 132 | 0.180 |
Why?
|
| Frontal Lobe | 2 | 2016 | 131 | 0.180 |
Why?
|
| Linear Models | 2 | 2021 | 438 | 0.180 |
Why?
|
| Water | 2 | 2022 | 307 | 0.180 |
Why?
|
| Aspartate Aminotransferases | 3 | 2013 | 75 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 2005 | 33 | 0.180 |
Why?
|
| Catheter Ablation | 2 | 2016 | 266 | 0.180 |
Why?
|
| Gulf War | 3 | 2018 | 4 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2021 | 684 | 0.180 |
Why?
|
| Phenotype | 3 | 2022 | 2579 | 0.180 |
Why?
|
| ras Proteins | 3 | 2013 | 134 | 0.180 |
Why?
|
| Cerebrovascular Circulation | 4 | 2017 | 244 | 0.180 |
Why?
|
| Lipodystrophy | 1 | 2001 | 3 | 0.170 |
Why?
|
| Panniculitis, Peritoneal | 1 | 2001 | 4 | 0.170 |
Why?
|
| Liver Failure, Acute | 2 | 2016 | 39 | 0.170 |
Why?
|
| Mice, Knockout | 13 | 2021 | 2163 | 0.170 |
Why?
|
| Gastritis, Hypertrophic | 1 | 2001 | 4 | 0.170 |
Why?
|
| Upper Extremity | 1 | 2022 | 65 | 0.170 |
Why?
|
| Mesentery | 1 | 2001 | 45 | 0.170 |
Why?
|
| Neoplasm Metastasis | 2 | 2021 | 1103 | 0.170 |
Why?
|
| RNA, Messenger | 9 | 2021 | 2092 | 0.170 |
Why?
|
| Colonic Pouches | 1 | 2022 | 97 | 0.170 |
Why?
|
| Peristalsis | 1 | 2000 | 10 | 0.170 |
Why?
|
| Bacteria | 2 | 2023 | 517 | 0.170 |
Why?
|
| Proctocolectomy, Restorative | 1 | 2022 | 115 | 0.170 |
Why?
|
| Plasma Cells | 1 | 2021 | 88 | 0.170 |
Why?
|
| Gallbladder Neoplasms | 1 | 2020 | 23 | 0.170 |
Why?
|
| Cytomegalovirus Infections | 2 | 2001 | 155 | 0.170 |
Why?
|
| Celiac Disease | 1 | 2023 | 219 | 0.170 |
Why?
|
| Hand | 1 | 2022 | 168 | 0.170 |
Why?
|
| Prospective Studies | 5 | 2018 | 4671 | 0.160 |
Why?
|
| Lifting | 1 | 2020 | 12 | 0.160 |
Why?
|
| Portal Vein | 1 | 2021 | 122 | 0.160 |
Why?
|
| Congenital Hyperinsulinism | 1 | 2020 | 15 | 0.160 |
Why?
|
| Memory, Episodic | 1 | 2021 | 62 | 0.160 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2010 | 162 | 0.160 |
Why?
|
| Hepatitis, Alcoholic | 2 | 2016 | 18 | 0.160 |
Why?
|
| Symptom Assessment | 1 | 2020 | 71 | 0.160 |
Why?
|
| Polyethylene Glycols | 3 | 2008 | 377 | 0.160 |
Why?
|
| Smooth Muscle Tumor | 1 | 2020 | 5 | 0.160 |
Why?
|
| Neoplasm Staging | 7 | 2018 | 2081 | 0.160 |
Why?
|
| Self Report | 3 | 2016 | 328 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2003 | 668 | 0.160 |
Why?
|
| Isoenzymes | 4 | 2003 | 278 | 0.160 |
Why?
|
| Chlamydia trachomatis | 1 | 2019 | 16 | 0.160 |
Why?
|
| Endoscopy, Digestive System | 3 | 2017 | 72 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 1469 | 0.160 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2021 | 187 | 0.160 |
Why?
|
| Cyclooxygenase 2 | 7 | 2009 | 100 | 0.160 |
Why?
|
| Intestinal Obstruction | 1 | 2000 | 94 | 0.160 |
Why?
|
| Seroepidemiologic Studies | 1 | 2019 | 57 | 0.160 |
Why?
|
| Living Donors | 4 | 2022 | 348 | 0.160 |
Why?
|
| Adenomatous Polyps | 1 | 2019 | 15 | 0.160 |
Why?
|
| Tinnitus | 2 | 2017 | 24 | 0.160 |
Why?
|
| Cetuximab | 2 | 2018 | 119 | 0.150 |
Why?
|
| CpG Islands | 2 | 2010 | 169 | 0.150 |
Why?
|
| Suture Techniques | 1 | 2000 | 143 | 0.150 |
Why?
|
| Movement | 1 | 2022 | 325 | 0.150 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2019 | 11 | 0.150 |
Why?
|
| Electric Stimulation Therapy | 2 | 2017 | 54 | 0.150 |
Why?
|
| Transcription, Genetic | 3 | 2016 | 1192 | 0.150 |
Why?
|
| Drug Monitoring | 2 | 2017 | 120 | 0.150 |
Why?
|
| Models, Psychological | 1 | 2020 | 166 | 0.150 |
Why?
|
| Disability Evaluation | 2 | 2020 | 171 | 0.150 |
Why?
|
| Autoantibodies | 3 | 2014 | 281 | 0.150 |
Why?
|
| Databases, Factual | 6 | 2020 | 1010 | 0.150 |
Why?
|
| Epithelial Cells | 7 | 2016 | 710 | 0.150 |
Why?
|
| Microscopy, Acoustic | 1 | 2018 | 8 | 0.150 |
Why?
|
| Sildenafil Citrate | 1 | 2019 | 24 | 0.150 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2019 | 13 | 0.150 |
Why?
|
| Cholinergic Neurons | 1 | 2018 | 11 | 0.150 |
Why?
|
| Ursodeoxycholic Acid | 3 | 2003 | 26 | 0.150 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 186 | 0.150 |
Why?
|
| Phacoemulsification | 1 | 2018 | 19 | 0.150 |
Why?
|
| DNA Methylation | 3 | 2020 | 703 | 0.140 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2018 | 39 | 0.140 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2021 | 247 | 0.140 |
Why?
|
| CDX2 Transcription Factor | 2 | 2016 | 7 | 0.140 |
Why?
|
| Research Report | 2 | 2016 | 43 | 0.140 |
Why?
|
| Neovascularization, Pathologic | 2 | 2012 | 355 | 0.140 |
Why?
|
| Graft Survival | 7 | 2024 | 942 | 0.140 |
Why?
|
| Proteins | 2 | 2005 | 816 | 0.140 |
Why?
|
| Biopsy, Needle | 8 | 2009 | 232 | 0.140 |
Why?
|
| Crops, Agricultural | 1 | 2018 | 18 | 0.140 |
Why?
|
| Radiology | 1 | 2021 | 206 | 0.140 |
Why?
|
| Immunocompromised Host | 2 | 2024 | 147 | 0.140 |
Why?
|
| Coronary Artery Bypass | 1 | 2000 | 252 | 0.140 |
Why?
|
| Acoustic Stimulation | 1 | 2018 | 131 | 0.140 |
Why?
|
| Transcription Factors | 6 | 2014 | 1730 | 0.140 |
Why?
|
| Liver Cirrhosis, Alcoholic | 2 | 2016 | 23 | 0.140 |
Why?
|
| Biomass | 1 | 2018 | 43 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2003 | 488 | 0.140 |
Why?
|
| Neurovascular Coupling | 1 | 2018 | 5 | 0.140 |
Why?
|
| Peptide Fragments | 3 | 2022 | 477 | 0.140 |
Why?
|
| Equipment Failure | 1 | 2018 | 128 | 0.140 |
Why?
|
| Dextran Sulfate | 4 | 2012 | 70 | 0.140 |
Why?
|
| Models, Neurological | 1 | 2021 | 434 | 0.140 |
Why?
|
| Radiography | 3 | 2021 | 826 | 0.140 |
Why?
|
| Agriculture | 1 | 2018 | 44 | 0.140 |
Why?
|
| Food Supply | 1 | 2018 | 31 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 226 | 0.140 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2011 | 157 | 0.140 |
Why?
|
| Lewy Body Disease | 1 | 2018 | 11 | 0.140 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2018 | 25 | 0.140 |
Why?
|
| Analysis of Variance | 5 | 2016 | 910 | 0.140 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2017 | 4 | 0.140 |
Why?
|
| Blotting, Western | 6 | 2011 | 798 | 0.140 |
Why?
|
| Science | 1 | 2018 | 37 | 0.140 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 554 | 0.140 |
Why?
|
| Fatal Outcome | 4 | 2009 | 304 | 0.140 |
Why?
|
| Endoscopy | 3 | 2020 | 374 | 0.140 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2017 | 12 | 0.140 |
Why?
|
| Psychotherapy, Group | 1 | 2017 | 37 | 0.140 |
Why?
|
| Mitochondria, Liver | 2 | 2021 | 29 | 0.140 |
Why?
|
| Risk Assessment | 7 | 2010 | 2480 | 0.140 |
Why?
|
| Temporal Lobe | 1 | 2019 | 195 | 0.140 |
Why?
|
| Animal Diseases | 1 | 2017 | 5 | 0.140 |
Why?
|
| Rectal Neoplasms | 2 | 2012 | 134 | 0.140 |
Why?
|
| Anus Neoplasms | 1 | 2018 | 38 | 0.140 |
Why?
|
| Influenza, Human | 1 | 2021 | 370 | 0.140 |
Why?
|
| Signal Transduction | 11 | 2017 | 3586 | 0.140 |
Why?
|
| Carcinogens | 6 | 2019 | 106 | 0.130 |
Why?
|
| Rainforest | 1 | 2017 | 17 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2013 | 701 | 0.130 |
Why?
|
| Thrombospondins | 1 | 2017 | 15 | 0.130 |
Why?
|
| Dissection | 1 | 2017 | 45 | 0.130 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2018 | 504 | 0.130 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 3 | 2003 | 37 | 0.130 |
Why?
|
| Tropical Climate | 1 | 2017 | 35 | 0.130 |
Why?
|
| Sustained Virologic Response | 1 | 2017 | 7 | 0.130 |
Why?
|
| Anthrax | 1 | 2017 | 31 | 0.130 |
Why?
|
| Receptors, Interleukin | 1 | 2017 | 39 | 0.130 |
Why?
|
| Occipital Lobe | 1 | 2017 | 25 | 0.130 |
Why?
|
| Communicable Diseases | 1 | 2018 | 69 | 0.130 |
Why?
|
| Animals, Wild | 1 | 2017 | 52 | 0.130 |
Why?
|
| Bacterial Proteins | 2 | 2019 | 922 | 0.130 |
Why?
|
| Gray Matter | 1 | 2017 | 43 | 0.130 |
Why?
|
| Collagen Type I | 1 | 2017 | 74 | 0.130 |
Why?
|
| Fibromyalgia | 1 | 2017 | 16 | 0.130 |
Why?
|
| Stroop Test | 1 | 2017 | 11 | 0.130 |
Why?
|
| Intraoperative Complications | 1 | 2018 | 197 | 0.130 |
Why?
|
| Up-Regulation | 6 | 2020 | 741 | 0.130 |
Why?
|
| Pathology | 1 | 2017 | 36 | 0.130 |
Why?
|
| Camptothecin | 1 | 2018 | 204 | 0.130 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2017 | 23 | 0.130 |
Why?
|
| Bacillus anthracis | 1 | 2017 | 74 | 0.130 |
Why?
|
| Patella | 1 | 2017 | 31 | 0.130 |
Why?
|
| Focal Adhesions | 1 | 2017 | 66 | 0.130 |
Why?
|
| Rats | 14 | 2012 | 4154 | 0.130 |
Why?
|
| Gyrus Cinguli | 1 | 2017 | 49 | 0.130 |
Why?
|
| ADAM17 Protein | 1 | 2016 | 9 | 0.130 |
Why?
|
| Transplantation, Isogeneic | 5 | 1999 | 40 | 0.130 |
Why?
|
| Chemokine CXCL2 | 1 | 2016 | 16 | 0.130 |
Why?
|
| Debridement | 1 | 2017 | 61 | 0.130 |
Why?
|
| Esophagus | 1 | 2017 | 111 | 0.130 |
Why?
|
| Esophagitis | 2 | 2013 | 43 | 0.120 |
Why?
|
| Fructose | 1 | 2016 | 36 | 0.120 |
Why?
|
| Histocytochemistry | 4 | 2017 | 132 | 0.120 |
Why?
|
| HLA Antigens | 2 | 2014 | 231 | 0.120 |
Why?
|
| Postsynaptic Potential Summation | 1 | 2016 | 1 | 0.120 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2016 | 8 | 0.120 |
Why?
|
| Renin | 1 | 2016 | 67 | 0.120 |
Why?
|
| Duodenal Neoplasms | 1 | 2016 | 21 | 0.120 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 49 | 0.120 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2008 | 28 | 0.120 |
Why?
|
| Acute Disease | 4 | 2023 | 872 | 0.120 |
Why?
|
| Brain Waves | 1 | 2016 | 36 | 0.120 |
Why?
|
| Intestines | 5 | 2004 | 431 | 0.120 |
Why?
|
| Ultrasonography, Interventional | 2 | 2013 | 125 | 0.120 |
Why?
|
| Pancreatitis | 2 | 2013 | 94 | 0.120 |
Why?
|
| Auditory Cortex | 1 | 2016 | 67 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 1 | 2016 | 62 | 0.120 |
Why?
|
| Knee Joint | 1 | 2017 | 166 | 0.120 |
Why?
|
| Eosinophilia | 2 | 2010 | 89 | 0.120 |
Why?
|
| Research Design | 1 | 2019 | 631 | 0.120 |
Why?
|
| Infant, Newborn | 5 | 2025 | 2614 | 0.120 |
Why?
|
| Transcription Factor AP-1 | 3 | 2008 | 66 | 0.120 |
Why?
|
| Behavior Rating Scale | 1 | 2015 | 6 | 0.120 |
Why?
|
| Age of Onset | 4 | 2018 | 344 | 0.120 |
Why?
|
| Language Disorders | 1 | 2015 | 11 | 0.120 |
Why?
|
| Mucins | 3 | 2016 | 40 | 0.120 |
Why?
|
| Anticonvulsants | 1 | 2016 | 133 | 0.120 |
Why?
|
| Hyperplasia | 3 | 2010 | 149 | 0.120 |
Why?
|
| Chicago | 3 | 2020 | 1503 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 935 | 0.120 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2015 | 16 | 0.110 |
Why?
|
| Transaminases | 3 | 2014 | 34 | 0.110 |
Why?
|
| Cholecalciferol | 2 | 2007 | 35 | 0.110 |
Why?
|
| Benzamides | 2 | 2014 | 248 | 0.110 |
Why?
|
| Frontotemporal Dementia | 1 | 2015 | 31 | 0.110 |
Why?
|
| Cell Line, Tumor | 7 | 2018 | 2794 | 0.110 |
Why?
|
| Mammals | 1 | 2017 | 261 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2017 | 111 | 0.110 |
Why?
|
| Lithiasis | 1 | 2014 | 2 | 0.110 |
Why?
|
| Electron Probe Microanalysis | 1 | 2015 | 8 | 0.110 |
Why?
|
| Valine | 1 | 2015 | 62 | 0.110 |
Why?
|
| Mental Status Schedule | 1 | 2015 | 27 | 0.110 |
Why?
|
| Vanadium | 1 | 2015 | 13 | 0.110 |
Why?
|
| Hybridization, Genetic | 1 | 2015 | 107 | 0.110 |
Why?
|
| Cholangiography | 1 | 2014 | 38 | 0.110 |
Why?
|
| Histoplasma | 2 | 2009 | 16 | 0.110 |
Why?
|
| Cholelithiasis | 1 | 2014 | 36 | 0.110 |
Why?
|
| Pupil | 1 | 2014 | 20 | 0.110 |
Why?
|
| Acyclovir | 1 | 2015 | 110 | 0.110 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2014 | 19 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2016 | 218 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 366 | 0.110 |
Why?
|
| Syndrome | 3 | 2004 | 453 | 0.110 |
Why?
|
| Causality | 1 | 2014 | 84 | 0.110 |
Why?
|
| Transforming Growth Factor alpha | 2 | 2016 | 50 | 0.110 |
Why?
|
| Receptor Cross-Talk | 1 | 2014 | 33 | 0.110 |
Why?
|
| Ligands | 4 | 2016 | 478 | 0.110 |
Why?
|
| Emotions | 2 | 2017 | 377 | 0.110 |
Why?
|
| Rats, Inbred F344 | 8 | 2008 | 165 | 0.110 |
Why?
|
| Vocabulary | 1 | 2014 | 16 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2012 | 944 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 301 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2010 | 246 | 0.110 |
Why?
|
| Panax | 2 | 2016 | 171 | 0.110 |
Why?
|
| West Nile virus | 1 | 2014 | 17 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2008 | 249 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2005 | 898 | 0.110 |
Why?
|
| Visual Cortex | 1 | 2017 | 265 | 0.110 |
Why?
|
| Pyrrolidines | 1 | 2014 | 62 | 0.110 |
Why?
|
| Neurology | 1 | 2015 | 83 | 0.110 |
Why?
|
| Autoimmune Diseases | 3 | 2013 | 257 | 0.110 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2010 | 14 | 0.110 |
Why?
|
| Blood Vessels | 2 | 2018 | 92 | 0.110 |
Why?
|
| Nasopharynx | 1 | 2014 | 51 | 0.110 |
Why?
|
| Streptococcus pneumoniae | 1 | 2014 | 56 | 0.110 |
Why?
|
| Cystadenoma | 1 | 2014 | 19 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 647 | 0.100 |
Why?
|
| ABO Blood-Group System | 1 | 2014 | 60 | 0.100 |
Why?
|
| Radiographic Image Enhancement | 1 | 2016 | 467 | 0.100 |
Why?
|
| Vidarabine | 2 | 2012 | 146 | 0.100 |
Why?
|
| Arousal | 1 | 2014 | 173 | 0.100 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 813 | 0.100 |
Why?
|
| Receptor, ErbB-2 | 1 | 2015 | 280 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 2642 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2018 | 1158 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 206 | 0.100 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2011 | 70 | 0.100 |
Why?
|
| Proteomics | 1 | 2015 | 269 | 0.100 |
Why?
|
| Microvessels | 2 | 2012 | 74 | 0.100 |
Why?
|
| Health Status | 1 | 2015 | 386 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 444 | 0.100 |
Why?
|
| Hepatitis E | 1 | 2013 | 5 | 0.100 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 514 | 0.100 |
Why?
|
| Tight Junctions | 2 | 2012 | 153 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2017 | 451 | 0.100 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 472 | 0.100 |
Why?
|
| Bilirubin | 2 | 2010 | 134 | 0.100 |
Why?
|
| Narcotic Antagonists | 1 | 2014 | 170 | 0.100 |
Why?
|
| Glycogen Synthase Kinase 3 | 2 | 2011 | 71 | 0.100 |
Why?
|
| Enteritis | 1 | 2013 | 23 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2014 | 599 | 0.100 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 180 | 0.100 |
Why?
|
| Texas | 1 | 2013 | 131 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 201 | 0.100 |
Why?
|
| Genetics, Population | 1 | 2015 | 437 | 0.090 |
Why?
|
| Azathioprine | 1 | 2013 | 125 | 0.090 |
Why?
|
| Reference Values | 3 | 2013 | 675 | 0.090 |
Why?
|
| Estrogen Receptor beta | 1 | 2012 | 26 | 0.090 |
Why?
|
| Contrast Media | 2 | 2015 | 1096 | 0.090 |
Why?
|
| CD8 Antigens | 4 | 1999 | 84 | 0.090 |
Why?
|
| Rectal Diseases | 1 | 2012 | 23 | 0.090 |
Why?
|
| Peptide Hormones | 1 | 2012 | 30 | 0.090 |
Why?
|
| Neuroimaging | 1 | 2013 | 135 | 0.090 |
Why?
|
| Cell Proliferation | 6 | 2019 | 1761 | 0.090 |
Why?
|
| Genes, ras | 4 | 2007 | 97 | 0.090 |
Why?
|
| Hamartoma | 1 | 2012 | 33 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2012 | 89 | 0.090 |
Why?
|
| Pancreatic Cyst | 1 | 2011 | 29 | 0.090 |
Why?
|
| Proof of Concept Study | 2 | 2025 | 57 | 0.090 |
Why?
|
| Genomics | 1 | 2017 | 855 | 0.090 |
Why?
|
| Diffusion Tensor Imaging | 3 | 2017 | 76 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2014 | 1973 | 0.090 |
Why?
|
| Bile | 1 | 2011 | 61 | 0.090 |
Why?
|
| Autopsy | 2 | 2022 | 129 | 0.090 |
Why?
|
| Nerve Net | 1 | 2015 | 407 | 0.090 |
Why?
|
| Proto-Oncogenes | 1 | 2011 | 61 | 0.090 |
Why?
|
| Gastroscopy | 2 | 2021 | 25 | 0.090 |
Why?
|
| Neuronal Plasticity | 1 | 2013 | 205 | 0.090 |
Why?
|
| Microtomy | 1 | 2011 | 10 | 0.090 |
Why?
|
| CD40 Antigens | 2 | 2001 | 44 | 0.090 |
Why?
|
| Cysts | 1 | 2012 | 104 | 0.090 |
Why?
|
| Dietary Fats | 1 | 2011 | 137 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 563 | 0.080 |
Why?
|
| Neoplasm, Residual | 2 | 2017 | 194 | 0.080 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 221 | 0.080 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2011 | 43 | 0.080 |
Why?
|
| Giant Cells | 1 | 2010 | 19 | 0.080 |
Why?
|
| Compression Bandages | 1 | 2010 | 7 | 0.080 |
Why?
|
| Microsatellite Repeats | 2 | 2015 | 151 | 0.080 |
Why?
|
| Receptor, EphB2 | 1 | 2010 | 3 | 0.080 |
Why?
|
| Incidence | 5 | 2017 | 1715 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2013 | 369 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2025 | 688 | 0.080 |
Why?
|
| Alkaline Phosphatase | 1 | 2010 | 136 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 1 | 2010 | 86 | 0.080 |
Why?
|
| Brazil | 1 | 2010 | 82 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2009 | 1105 | 0.080 |
Why?
|
| Mucin-6 | 1 | 2010 | 2 | 0.080 |
Why?
|
| Matrix Metalloproteinase 7 | 2 | 2009 | 11 | 0.080 |
Why?
|
| Liver Function Tests | 5 | 2013 | 94 | 0.080 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2010 | 48 | 0.080 |
Why?
|
| Minimally Invasive Surgical Procedures | 4 | 2009 | 287 | 0.080 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2009 | 17 | 0.080 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2011 | 81 | 0.080 |
Why?
|
| Endosonography | 2 | 2013 | 101 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2007 | 80 | 0.080 |
Why?
|
| Integrin beta3 | 1 | 2010 | 32 | 0.080 |
Why?
|
| Endangered Species | 1 | 2010 | 26 | 0.080 |
Why?
|
| Microsatellite Instability | 1 | 2010 | 64 | 0.080 |
Why?
|
| Commerce | 1 | 2010 | 31 | 0.080 |
Why?
|
| United Kingdom | 1 | 2010 | 192 | 0.080 |
Why?
|
| Cell Differentiation | 4 | 2012 | 1666 | 0.080 |
Why?
|
| Abdominal Pain | 2 | 2013 | 145 | 0.080 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2011 | 108 | 0.080 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2009 | 86 | 0.080 |
Why?
|
| Antigens, CD34 | 1 | 2010 | 163 | 0.080 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2009 | 209 | 0.080 |
Why?
|
| HCT116 Cells | 3 | 2017 | 164 | 0.080 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 107 | 0.080 |
Why?
|
| Adenoma, Liver Cell | 1 | 2009 | 3 | 0.080 |
Why?
|
| Dependovirus | 1 | 2009 | 37 | 0.080 |
Why?
|
| Age Factors | 1 | 2014 | 1963 | 0.080 |
Why?
|
| Glucagon-Secreting Cells | 1 | 2009 | 27 | 0.080 |
Why?
|
| Retroperitoneal Space | 1 | 2009 | 42 | 0.080 |
Why?
|
| Delphi Technique | 2 | 2025 | 136 | 0.080 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2010 | 50 | 0.080 |
Why?
|
| Malawi | 2 | 2019 | 9 | 0.080 |
Why?
|
| Anastomosis, Surgical | 1 | 2010 | 283 | 0.070 |
Why?
|
| Caco-2 Cells | 3 | 2012 | 125 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 277 | 0.070 |
Why?
|
| DNA Primers | 3 | 2008 | 548 | 0.070 |
Why?
|
| Leucovorin | 2 | 2020 | 227 | 0.070 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2008 | 6 | 0.070 |
Why?
|
| Infant Mortality | 2 | 2019 | 67 | 0.070 |
Why?
|
| Sphingomonadaceae | 1 | 2008 | 2 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 558 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2010 | 383 | 0.070 |
Why?
|
| Iron | 1 | 2009 | 179 | 0.070 |
Why?
|
| Genotype | 4 | 2020 | 1882 | 0.070 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2009 | 201 | 0.070 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2008 | 22 | 0.070 |
Why?
|
| Chemical and Drug Induced Liver Injury, Chronic | 1 | 2008 | 2 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 191 | 0.070 |
Why?
|
| Triglycerides | 1 | 2009 | 236 | 0.070 |
Why?
|
| Cause of Death | 1 | 2009 | 278 | 0.070 |
Why?
|
| Diet | 1 | 2011 | 461 | 0.070 |
Why?
|
| Indomethacin | 1 | 2008 | 62 | 0.070 |
Why?
|
| Base Sequence | 4 | 2008 | 2344 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2008 | 215 | 0.070 |
Why?
|
| Cats | 1 | 2008 | 306 | 0.070 |
Why?
|
| Physicians | 1 | 2015 | 707 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 1773 | 0.070 |
Why?
|
| Genetic Vectors | 1 | 2009 | 446 | 0.070 |
Why?
|
| Mucin-1 | 2 | 2012 | 46 | 0.070 |
Why?
|
| Mastocytosis | 1 | 2007 | 14 | 0.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2019 | 46 | 0.070 |
Why?
|
| Neovascularization, Physiologic | 1 | 2008 | 145 | 0.070 |
Why?
|
| Immunoglobulin A | 2 | 2023 | 91 | 0.070 |
Why?
|
| Gene Expression | 4 | 2009 | 1322 | 0.070 |
Why?
|
| Cholangitis | 1 | 2007 | 19 | 0.070 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2007 | 30 | 0.070 |
Why?
|
| Amyloidosis | 1 | 2009 | 139 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2008 | 2781 | 0.070 |
Why?
|
| Hepacivirus | 1 | 2008 | 137 | 0.070 |
Why?
|
| Fluorouracil | 2 | 2020 | 555 | 0.070 |
Why?
|
| Regeneration | 1 | 2008 | 161 | 0.070 |
Why?
|
| Hepatic Encephalopathy | 2 | 1999 | 38 | 0.070 |
Why?
|
| Verbal Learning | 1 | 2007 | 30 | 0.070 |
Why?
|
| Genes, p53 | 1 | 2007 | 109 | 0.070 |
Why?
|
| Transcriptome | 1 | 2013 | 770 | 0.070 |
Why?
|
| Logistic Models | 3 | 2016 | 1268 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2009 | 1230 | 0.060 |
Why?
|
| Bacterial Toxins | 1 | 2007 | 115 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 305 | 0.060 |
Why?
|
| Pancreatectomy | 2 | 2021 | 168 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 312 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 4 | 2015 | 298 | 0.060 |
Why?
|
| Cholesterol | 1 | 2009 | 370 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 829 | 0.060 |
Why?
|
| Hematologic Neoplasms | 1 | 2010 | 372 | 0.060 |
Why?
|
| Algorithms | 2 | 2020 | 2014 | 0.060 |
Why?
|
| In Situ Hybridization | 2 | 2021 | 313 | 0.060 |
Why?
|
| Choledocholithiasis | 1 | 2006 | 14 | 0.060 |
Why?
|
| Cholecystectomy | 1 | 2006 | 26 | 0.060 |
Why?
|
| Fever | 2 | 2005 | 131 | 0.060 |
Why?
|
| Tacrolimus | 5 | 2003 | 373 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2006 | 4 | 0.060 |
Why?
|
| Amyloid | 2 | 2022 | 105 | 0.060 |
Why?
|
| Ecosystem | 1 | 2010 | 394 | 0.060 |
Why?
|
| Killer Cells, Natural | 1 | 2008 | 294 | 0.060 |
Why?
|
| Glycogen | 1 | 2006 | 60 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2006 | 18 | 0.060 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2006 | 11 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2021 | 2943 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2008 | 346 | 0.060 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2008 | 290 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2006 | 24 | 0.060 |
Why?
|
| Cell Division | 6 | 2007 | 705 | 0.060 |
Why?
|
| Receptors, Kainic Acid | 1 | 2005 | 13 | 0.060 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2005 | 6 | 0.060 |
Why?
|
| Suction | 1 | 2005 | 38 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 2860 | 0.060 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 84 | 0.060 |
Why?
|
| Ploidies | 2 | 1996 | 41 | 0.060 |
Why?
|
| Mediastinal Neoplasms | 1 | 2005 | 46 | 0.060 |
Why?
|
| Insulin-Secreting Cells | 1 | 2009 | 442 | 0.060 |
Why?
|
| Fiji | 1 | 2025 | 1 | 0.060 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 354 | 0.060 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2005 | 50 | 0.060 |
Why?
|
| Referral and Consultation | 2 | 2025 | 386 | 0.060 |
Why?
|
| Adenoma, Villous | 1 | 2005 | 2 | 0.060 |
Why?
|
| Angiotensin II | 2 | 2016 | 95 | 0.060 |
Why?
|
| Butanones | 1 | 2005 | 8 | 0.060 |
Why?
|
| Snail Family Transcription Factors | 3 | 2014 | 48 | 0.060 |
Why?
|
| Alcoholism | 2 | 2014 | 191 | 0.060 |
Why?
|
| Carcinoma, Basosquamous | 1 | 2004 | 1 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 1645 | 0.060 |
Why?
|
| Labor, Obstetric | 1 | 2025 | 48 | 0.060 |
Why?
|
| Cimicifuga | 1 | 2004 | 3 | 0.060 |
Why?
|
| Tanzania | 2 | 2018 | 49 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2019 | 465 | 0.060 |
Why?
|
| CD40 Ligand | 2 | 2003 | 77 | 0.050 |
Why?
|
| Awards and Prizes | 1 | 2025 | 37 | 0.050 |
Why?
|
| Surface-Active Agents | 1 | 2004 | 62 | 0.050 |
Why?
|
| Mucous Membrane | 3 | 2009 | 85 | 0.050 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2004 | 63 | 0.050 |
Why?
|
| Protein Kinase C | 2 | 2012 | 267 | 0.050 |
Why?
|
| Gastric Fundus | 1 | 2004 | 7 | 0.050 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2004 | 43 | 0.050 |
Why?
|
| RNA, Viral | 2 | 2017 | 311 | 0.050 |
Why?
|
| Protein Array Analysis | 1 | 2004 | 52 | 0.050 |
Why?
|
| Intestinal Neoplasms | 1 | 2004 | 70 | 0.050 |
Why?
|
| Polyps | 1 | 2004 | 26 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 303 | 0.050 |
Why?
|
| Necrosis | 4 | 2013 | 210 | 0.050 |
Why?
|
| Cell Nucleus | 2 | 2004 | 623 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2019 | 938 | 0.050 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2003 | 12 | 0.050 |
Why?
|
| Asphyxia | 1 | 2003 | 12 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2018 | 908 | 0.050 |
Why?
|
| CD28 Antigens | 2 | 2003 | 94 | 0.050 |
Why?
|
| Duodenum | 1 | 2023 | 112 | 0.050 |
Why?
|
| Phytotherapy | 1 | 2004 | 138 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 90 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 3 | 2017 | 930 | 0.050 |
Why?
|
| Wound Healing | 2 | 2020 | 378 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2005 | 418 | 0.050 |
Why?
|
| Liver Regeneration | 1 | 2003 | 36 | 0.050 |
Why?
|
| Bathing Beaches | 1 | 2022 | 1 | 0.050 |
Why?
|
| Cholagogues and Choleretics | 1 | 2002 | 10 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 370 | 0.050 |
Why?
|
| Bias | 1 | 2023 | 139 | 0.050 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2022 | 13 | 0.050 |
Why?
|
| Metaplasia | 2 | 2016 | 39 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2020 | 358 | 0.050 |
Why?
|
| Michigan | 1 | 2022 | 57 | 0.050 |
Why?
|
| Immunoconjugates | 2 | 2003 | 131 | 0.050 |
Why?
|
| Liver Glycogen | 1 | 2002 | 5 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2019 | 1054 | 0.050 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 43 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2003 | 294 | 0.050 |
Why?
|
| Chlamydophila Infections | 1 | 2002 | 3 | 0.050 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2002 | 13 | 0.050 |
Why?
|
| Constipation | 1 | 2003 | 69 | 0.050 |
Why?
|
| Mitotic Index | 1 | 2022 | 22 | 0.050 |
Why?
|
| Neoplasms | 3 | 2017 | 3250 | 0.050 |
Why?
|
| Paget's Disease, Mammary | 1 | 2001 | 3 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 98 | 0.050 |
Why?
|
| Atrophy | 1 | 2022 | 132 | 0.050 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2002 | 20 | 0.050 |
Why?
|
| Paget Disease, Extramammary | 1 | 2001 | 8 | 0.050 |
Why?
|
| Esophagitis, Peptic | 1 | 2002 | 10 | 0.050 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2022 | 12 | 0.050 |
Why?
|
| Ileum | 2 | 2019 | 169 | 0.050 |
Why?
|
| Microscopy, Electron | 2 | 2017 | 510 | 0.050 |
Why?
|
| Mucin-2 | 3 | 2012 | 12 | 0.050 |
Why?
|
| Mice, Inbred C3H | 5 | 2001 | 372 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 1268 | 0.050 |
Why?
|
| Plasma Exchange | 1 | 2002 | 28 | 0.050 |
Why?
|
| Piperazines | 1 | 2003 | 296 | 0.040 |
Why?
|
| Enalapril | 1 | 2001 | 12 | 0.040 |
Why?
|
| Life Expectancy | 1 | 2022 | 91 | 0.040 |
Why?
|
| Transplantation Chimera | 2 | 2003 | 84 | 0.040 |
Why?
|
| Oxygen | 2 | 2017 | 788 | 0.040 |
Why?
|
| Gastroenteritis | 1 | 2001 | 26 | 0.040 |
Why?
|
| Mice, Inbred Strains | 4 | 2008 | 297 | 0.040 |
Why?
|
| tau Proteins | 1 | 2022 | 98 | 0.040 |
Why?
|
| Alemtuzumab | 2 | 2012 | 90 | 0.040 |
Why?
|
| Anticarcinogenic Agents | 2 | 2006 | 71 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 1096 | 0.040 |
Why?
|
| Calcitriol | 2 | 2007 | 173 | 0.040 |
Why?
|
| Organ Preservation | 1 | 2022 | 130 | 0.040 |
Why?
|
| Survival Analysis | 4 | 2008 | 1546 | 0.040 |
Why?
|
| Carcinoma, Papillary | 1 | 2002 | 161 | 0.040 |
Why?
|
| Karyopherins | 1 | 2020 | 15 | 0.040 |
Why?
|
| Memory, Long-Term | 1 | 2021 | 29 | 0.040 |
Why?
|
| Probability | 3 | 2009 | 365 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2013 | 299 | 0.040 |
Why?
|
| Learning Curve | 1 | 2021 | 23 | 0.040 |
Why?
|
| New York | 1 | 2021 | 75 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2003 | 386 | 0.040 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 122 | 0.040 |
Why?
|
| Glucagon | 1 | 2021 | 115 | 0.040 |
Why?
|
| Cytokines | 2 | 2022 | 872 | 0.040 |
Why?
|
| Perfusion | 1 | 2022 | 266 | 0.040 |
Why?
|
| Interferon Regulatory Factors | 1 | 2021 | 77 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2020 | 38 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 2422 | 0.040 |
Why?
|
| Cytosol | 1 | 2021 | 198 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2003 | 810 | 0.040 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2001 | 109 | 0.040 |
Why?
|
| Heat Stroke | 1 | 2000 | 9 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2012 | 340 | 0.040 |
Why?
|
| Chromans | 1 | 2000 | 29 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 125 | 0.040 |
Why?
|
| Outpatients | 1 | 2021 | 105 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2000 | 76 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2015 | 713 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 1010 | 0.040 |
Why?
|
| Injections | 1 | 2020 | 126 | 0.040 |
Why?
|
| Amyloid beta-Peptides | 1 | 2022 | 246 | 0.040 |
Why?
|
| Fatty Acids | 2 | 2012 | 153 | 0.040 |
Why?
|
| Thiazolidinediones | 1 | 2000 | 76 | 0.040 |
Why?
|
| Interleukin-1beta | 2 | 2012 | 89 | 0.040 |
Why?
|
| Seasons | 1 | 2021 | 246 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 303 | 0.040 |
Why?
|
| Mentors | 1 | 2021 | 101 | 0.040 |
Why?
|
| Microtubules | 1 | 2000 | 134 | 0.040 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 1999 | 118 | 0.040 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2012 | 68 | 0.040 |
Why?
|
| Integrases | 1 | 2019 | 67 | 0.040 |
Why?
|
| Thiazoles | 1 | 2000 | 130 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2021 | 362 | 0.040 |
Why?
|
| Intestinal Polyps | 1 | 2019 | 27 | 0.040 |
Why?
|
| B7-1 Antigen | 1 | 1999 | 75 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 224 | 0.040 |
Why?
|
| Chronic Disease | 4 | 2011 | 983 | 0.040 |
Why?
|
| Reference Standards | 1 | 2019 | 150 | 0.040 |
Why?
|
| Immunoglobulin G | 2 | 2013 | 481 | 0.040 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2003 | 423 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 2494 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 62 | 0.040 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2018 | 27 | 0.040 |
Why?
|
| Vitamins | 1 | 2019 | 86 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 253 | 0.040 |
Why?
|
| Dextrans | 1 | 2018 | 78 | 0.040 |
Why?
|
| Niger | 1 | 2018 | 4 | 0.040 |
Why?
|
| Homeostasis | 1 | 2021 | 467 | 0.040 |
Why?
|
| Transfection | 2 | 2012 | 909 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1998 | 80 | 0.040 |
Why?
|
| T-Lymphocytes | 3 | 2014 | 1316 | 0.040 |
Why?
|
| Technology | 1 | 2018 | 35 | 0.030 |
Why?
|
| Functional Neuroimaging | 1 | 2018 | 32 | 0.030 |
Why?
|
| Illinois | 2 | 2010 | 531 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 81 | 0.030 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 60 | 0.030 |
Why?
|
| Acinar Cells | 1 | 2017 | 8 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2018 | 56 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2012 | 70 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2018 | 100 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2018 | 196 | 0.030 |
Why?
|
| Parks, Recreational | 1 | 2017 | 5 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2017 | 25 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2001 | 382 | 0.030 |
Why?
|
| Pregnancy | 1 | 2025 | 3240 | 0.030 |
Why?
|
| DNA, Neoplasm | 2 | 1996 | 272 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 554 | 0.030 |
Why?
|
| Mice, Inbred A | 2 | 2007 | 23 | 0.030 |
Why?
|
| Calibration | 1 | 2017 | 108 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 1998 | 134 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2000 | 377 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2014 | 1267 | 0.030 |
Why?
|
| Liver Abscess | 1 | 1997 | 10 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1997 | 113 | 0.030 |
Why?
|
| Diptera | 1 | 2017 | 47 | 0.030 |
Why?
|
| Insulin Resistance | 2 | 2009 | 382 | 0.030 |
Why?
|
| Candidiasis | 1 | 1997 | 39 | 0.030 |
Why?
|
| Zanthoxylum | 1 | 2016 | 9 | 0.030 |
Why?
|
| Zingiberaceae | 1 | 2016 | 10 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2012 | 126 | 0.030 |
Why?
|
| Medicine, Traditional | 1 | 2016 | 8 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 162 | 0.030 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 55 | 0.030 |
Why?
|
| Public Health | 1 | 2018 | 155 | 0.030 |
Why?
|
| Allopurinol | 1 | 2017 | 78 | 0.030 |
Why?
|
| Gout Suppressants | 1 | 2017 | 35 | 0.030 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2016 | 21 | 0.030 |
Why?
|
| Hydralazine | 1 | 2016 | 21 | 0.030 |
Why?
|
| Estradiol | 2 | 2012 | 256 | 0.030 |
Why?
|
| Fumarates | 1 | 2016 | 20 | 0.030 |
Why?
|
| Tissue Scaffolds | 1 | 2017 | 129 | 0.030 |
Why?
|
| Esophageal Mucosa | 1 | 2016 | 4 | 0.030 |
Why?
|
| Anemia | 1 | 2017 | 137 | 0.030 |
Why?
|
| Spiro Compounds | 1 | 2016 | 30 | 0.030 |
Why?
|
| Extinction, Biological | 1 | 2017 | 97 | 0.030 |
Why?
|
| Amides | 1 | 2016 | 56 | 0.030 |
Why?
|
| Anisotropy | 1 | 2016 | 65 | 0.030 |
Why?
|
| Smoking | 1 | 2020 | 653 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 188 | 0.030 |
Why?
|
| Gout | 1 | 2017 | 75 | 0.030 |
Why?
|
| Quinazolines | 2 | 2008 | 216 | 0.030 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2016 | 16 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 750 | 0.030 |
Why?
|
| Tumor Virus Infections | 1 | 1996 | 83 | 0.030 |
Why?
|
| Diet, Western | 1 | 2016 | 45 | 0.030 |
Why?
|
| Central African Republic | 1 | 2015 | 3 | 0.030 |
Why?
|
| Democratic Republic of the Congo | 1 | 2015 | 8 | 0.030 |
Why?
|
| Africa, Western | 1 | 2015 | 12 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 2017 | 180 | 0.030 |
Why?
|
| Fatigue | 1 | 2017 | 185 | 0.030 |
Why?
|
| Neoplasms, Experimental | 2 | 2011 | 271 | 0.030 |
Why?
|
| Grassland | 1 | 2015 | 7 | 0.030 |
Why?
|
| Y Chromosome | 1 | 2015 | 31 | 0.030 |
Why?
|
| Diclofenac | 1 | 1995 | 4 | 0.030 |
Why?
|
| Forests | 1 | 2015 | 29 | 0.030 |
Why?
|
| Cerebral Palsy | 1 | 2016 | 96 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 1996 | 126 | 0.030 |
Why?
|
| Uganda | 1 | 2015 | 46 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2007 | 3041 | 0.030 |
Why?
|
| Blood Coagulation Disorders | 1 | 2016 | 67 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 360 | 0.030 |
Why?
|
| Pan troglodytes | 1 | 2017 | 205 | 0.030 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 1995 | 23 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 535 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2016 | 97 | 0.030 |
Why?
|
| Blood Glucose | 2 | 2009 | 873 | 0.030 |
Why?
|
| Hypertension | 1 | 2001 | 777 | 0.030 |
Why?
|
| Granuloma | 1 | 1995 | 65 | 0.030 |
Why?
|
| RNA Interference | 2 | 2007 | 385 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 103 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 328 | 0.030 |
Why?
|
| Fertility | 1 | 2015 | 119 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 1195 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2016 | 133 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 901 | 0.030 |
Why?
|
| Masoprocol | 1 | 1995 | 3 | 0.030 |
Why?
|
| Intellectual Disability | 1 | 2016 | 203 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2016 | 136 | 0.030 |
Why?
|
| Piperidines | 1 | 2016 | 171 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2015 | 257 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2015 | 92 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 192 | 0.030 |
Why?
|
| Postoperative Period | 2 | 2006 | 318 | 0.030 |
Why?
|
| Plants, Medicinal | 1 | 1995 | 40 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2015 | 197 | 0.030 |
Why?
|
| Antibodies, Bacterial | 2 | 2008 | 106 | 0.030 |
Why?
|
| Mydriasis | 1 | 2014 | 2 | 0.030 |
Why?
|
| Miosis | 1 | 2014 | 10 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2017 | 348 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1994 | 41 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2017 | 744 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2019 | 703 | 0.030 |
Why?
|
| Splenectomy | 1 | 2014 | 82 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 323 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 327 | 0.030 |
Why?
|
| Gambia | 1 | 2014 | 2 | 0.030 |
Why?
|
| Gadolinium | 1 | 2015 | 106 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 379 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2012 | 514 | 0.030 |
Why?
|
| Melanoma | 1 | 1999 | 497 | 0.030 |
Why?
|
| Caspase 3 | 2 | 2004 | 164 | 0.030 |
Why?
|
| Immunization Programs | 1 | 2014 | 26 | 0.030 |
Why?
|
| Caspases | 2 | 2004 | 156 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 1382 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 2014 | 33 | 0.030 |
Why?
|
| Forkhead Box Protein L2 | 1 | 2014 | 3 | 0.030 |
Why?
|
| Narcotics | 1 | 2014 | 72 | 0.030 |
Why?
|
| Pain | 1 | 2017 | 426 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 819 | 0.030 |
Why?
|
| Carrier State | 1 | 2014 | 40 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 413 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 2014 | 27 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2014 | 109 | 0.030 |
Why?
|
| Complement C4b | 1 | 2014 | 33 | 0.030 |
Why?
|
| Fentanyl | 1 | 2014 | 87 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2015 | 404 | 0.030 |
Why?
|
| Spouses | 1 | 2014 | 32 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2013 | 26 | 0.030 |
Why?
|
| Glycolysis | 1 | 2015 | 192 | 0.030 |
Why?
|
| Morphine | 1 | 2014 | 130 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 397 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2014 | 141 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 70 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 1999 | 625 | 0.030 |
Why?
|
| Rest | 1 | 2013 | 53 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 501 | 0.030 |
Why?
|
| Hepatitis E virus | 1 | 2013 | 5 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2000 | 828 | 0.020 |
Why?
|
| Naltrexone | 1 | 2014 | 139 | 0.020 |
Why?
|
| Roseolovirus Infections | 1 | 2013 | 9 | 0.020 |
Why?
|
| Rural Population | 1 | 2014 | 171 | 0.020 |
Why?
|
| Herpesvirus 6, Human | 1 | 2013 | 21 | 0.020 |
Why?
|
| Ganciclovir | 1 | 2013 | 52 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 195 | 0.020 |
Why?
|
| Capillaries | 1 | 2013 | 86 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 1999 | 812 | 0.020 |
Why?
|
| Flow Cytometry | 3 | 2003 | 727 | 0.020 |
Why?
|
| Gluconeogenesis | 1 | 2012 | 15 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2013 | 395 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 1133 | 0.020 |
Why?
|
| Lipogenesis | 1 | 2012 | 25 | 0.020 |
Why?
|
| Bile Ducts | 2 | 2003 | 61 | 0.020 |
Why?
|
| Epilepsy | 1 | 2016 | 451 | 0.020 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2012 | 33 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2012 | 179 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2013 | 121 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2013 | 479 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2013 | 274 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 417 | 0.020 |
Why?
|
| Fluorescein | 1 | 2011 | 14 | 0.020 |
Why?
|
| Physostigmine | 1 | 2011 | 20 | 0.020 |
Why?
|
| Fasting | 1 | 2012 | 164 | 0.020 |
Why?
|
| Veterans Health | 1 | 2011 | 19 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2012 | 72 | 0.020 |
Why?
|
| Abatacept | 2 | 2003 | 88 | 0.020 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2011 | 49 | 0.020 |
Why?
|
| Phylogeny | 1 | 2017 | 1275 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2013 | 333 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2007 | 2092 | 0.020 |
Why?
|
| Mucin 5AC | 2 | 2001 | 8 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2012 | 110 | 0.020 |
Why?
|
| G1 Phase | 1 | 2011 | 66 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 2 | 2002 | 103 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2012 | 127 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2011 | 198 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2011 | 45 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 257 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 377 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2012 | 329 | 0.020 |
Why?
|
| Fats | 1 | 2010 | 12 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 411 | 0.020 |
Why?
|
| Enzyme Inhibitors | 2 | 2007 | 657 | 0.020 |
Why?
|
| Alagille Syndrome | 1 | 2010 | 5 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2012 | 184 | 0.020 |
Why?
|
| Macrophages | 1 | 2014 | 626 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 797 | 0.020 |
Why?
|
| Hypopituitarism | 1 | 2010 | 19 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2012 | 281 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 119 | 0.020 |
Why?
|
| Biliary Atresia | 1 | 2010 | 24 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 192 | 0.020 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2010 | 16 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2010 | 23 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 668 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2010 | 72 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1791 | 0.020 |
Why?
|
| Zambia | 1 | 2010 | 9 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2015 | 983 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 214 | 0.020 |
Why?
|
| Tissue Donors | 1 | 1994 | 542 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2012 | 467 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2011 | 236 | 0.020 |
Why?
|
| Skin Transplantation | 2 | 2003 | 193 | 0.020 |
Why?
|
| Crime | 1 | 2010 | 38 | 0.020 |
Why?
|
| Models, Biological | 2 | 2012 | 1815 | 0.020 |
Why?
|
| Trees | 1 | 2010 | 46 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2010 | 226 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 134 | 0.020 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 2009 | 25 | 0.020 |
Why?
|
| Hemochromatosis Protein | 1 | 2009 | 7 | 0.020 |
Why?
|
| Jejunum | 2 | 2001 | 80 | 0.020 |
Why?
|
| Cyclosporine | 2 | 2003 | 242 | 0.020 |
Why?
|
| Population Dynamics | 1 | 2010 | 144 | 0.020 |
Why?
|
| Papio | 1 | 2009 | 87 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1157 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2009 | 50 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 771 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2010 | 255 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 220 | 0.020 |
Why?
|
| Glucose | 1 | 2012 | 701 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 311 | 0.020 |
Why?
|
| Point Mutation | 1 | 2009 | 247 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2012 | 469 | 0.020 |
Why?
|
| Keloid | 1 | 2008 | 8 | 0.020 |
Why?
|
| Granulation Tissue | 1 | 2008 | 15 | 0.020 |
Why?
|
| Endometrium | 1 | 2008 | 52 | 0.020 |
Why?
|
| Ribavirin | 1 | 2008 | 40 | 0.020 |
Why?
|
| Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2008 | 2 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2008 | 72 | 0.020 |
Why?
|
| Cyclin D | 1 | 2008 | 15 | 0.020 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2008 | 14 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2008 | 138 | 0.020 |
Why?
|
| Antigens, CD1d | 1 | 2008 | 32 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2009 | 336 | 0.020 |
Why?
|
| Antigens, CD1 | 1 | 2008 | 37 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 301 | 0.020 |
Why?
|
| Survival Rate | 2 | 2007 | 1986 | 0.020 |
Why?
|
| Cyclins | 1 | 2008 | 81 | 0.020 |
Why?
|
| Osteoarthritis, Hip | 1 | 2008 | 22 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2001 | 3147 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2008 | 89 | 0.020 |
Why?
|
| Viral Load | 1 | 2008 | 164 | 0.020 |
Why?
|
| Ulcer | 1 | 2007 | 38 | 0.020 |
Why?
|
| Permeability | 1 | 2007 | 144 | 0.020 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2007 | 45 | 0.020 |
Why?
|
| Scattering, Radiation | 1 | 2007 | 122 | 0.020 |
Why?
|
| Kinetics | 2 | 2000 | 1562 | 0.020 |
Why?
|
| Hepatectomy | 1 | 2008 | 178 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2007 | 112 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 98 | 0.020 |
Why?
|
| Family Health | 1 | 2007 | 159 | 0.020 |
Why?
|
| Calcium | 1 | 2012 | 1205 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2007 | 35 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 124 | 0.020 |
Why?
|
| Obesity | 1 | 2014 | 1034 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2007 | 360 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2007 | 368 | 0.020 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2006 | 8 | 0.020 |
Why?
|
| Inclusion Bodies | 1 | 2006 | 33 | 0.020 |
Why?
|
| Europe | 1 | 2007 | 349 | 0.020 |
Why?
|
| Quality of Life | 1 | 2015 | 1816 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 1034 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 422 | 0.020 |
Why?
|
| Muromonab-CD3 | 2 | 1996 | 70 | 0.020 |
Why?
|
| Pathology, Surgical | 1 | 2006 | 13 | 0.020 |
Why?
|
| Hepatitis B, Chronic | 1 | 2006 | 34 | 0.020 |
Why?
|
| Leukemia, Myeloid | 1 | 2007 | 252 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2007 | 208 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 85 | 0.020 |
Why?
|
| Light | 1 | 2007 | 297 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2007 | 521 | 0.020 |
Why?
|
| Cell Line | 2 | 2001 | 2533 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2007 | 481 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2007 | 220 | 0.010 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2008 | 341 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 567 | 0.010 |
Why?
|
| Antibodies | 1 | 2007 | 357 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2006 | 288 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 2005 | 149 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 157 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 2005 | 47 | 0.010 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2005 | 15 | 0.010 |
Why?
|
| HT29 Cells | 1 | 2005 | 50 | 0.010 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2005 | 6 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2005 | 38 | 0.010 |
Why?
|
| Body Temperature | 1 | 2005 | 131 | 0.010 |
Why?
|
| GATA6 Transcription Factor | 1 | 2005 | 13 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2007 | 703 | 0.010 |
Why?
|
| src-Family Kinases | 1 | 2005 | 70 | 0.010 |
Why?
|
| Haplotypes | 1 | 2007 | 650 | 0.010 |
Why?
|
| Chromosomal Instability | 1 | 2005 | 23 | 0.010 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2005 | 85 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 2007 | 485 | 0.010 |
Why?
|
| Drug Resistance | 2 | 1996 | 237 | 0.010 |
Why?
|
| Salivary Glands | 1 | 2004 | 20 | 0.010 |
Why?
|
| Hot Flashes | 1 | 2004 | 12 | 0.010 |
Why?
|
| Morpholinos | 1 | 2004 | 13 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 124 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 2004 | 79 | 0.010 |
Why?
|
| Insulin | 1 | 2009 | 1190 | 0.010 |
Why?
|
| Multigene Family | 1 | 2005 | 213 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2007 | 1083 | 0.010 |
Why?
|
| Morpholines | 1 | 2004 | 77 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2005 | 392 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2004 | 232 | 0.010 |
Why?
|
| Peptides | 1 | 2007 | 672 | 0.010 |
Why?
|
| Complementary Therapies | 1 | 2004 | 55 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2004 | 133 | 0.010 |
Why?
|
| Cell Movement | 1 | 2007 | 820 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2004 | 68 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2003 | 73 | 0.010 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2004 | 81 | 0.010 |
Why?
|
| Reoperation | 2 | 1997 | 707 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1798 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2005 | 252 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2003 | 127 | 0.010 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2003 | 17 | 0.010 |
Why?
|
| Transplantation | 1 | 2003 | 38 | 0.010 |
Why?
|
| Mitosis | 1 | 2003 | 159 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 273 | 0.010 |
Why?
|
| DNA Repair | 1 | 2005 | 376 | 0.010 |
Why?
|
| Mortality | 1 | 2003 | 154 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2005 | 394 | 0.010 |
Why?
|
| Random Allocation | 1 | 2002 | 327 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2002 | 89 | 0.010 |
Why?
|
| Bacterial Vaccines | 1 | 2002 | 45 | 0.010 |
Why?
|
| Spleen | 1 | 2003 | 439 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2005 | 444 | 0.010 |
Why?
|
| Vulva | 1 | 2001 | 23 | 0.010 |
Why?
|
| Peptide Library | 1 | 2002 | 85 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2002 | 128 | 0.010 |
Why?
|
| Scrotum | 1 | 2001 | 18 | 0.010 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2002 | 92 | 0.010 |
Why?
|
| Nipples | 1 | 2001 | 38 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 564 | 0.010 |
Why?
|
| Epitopes | 1 | 2002 | 258 | 0.010 |
Why?
|
| Portal System | 1 | 2001 | 13 | 0.010 |
Why?
|
| Urothelium | 1 | 2001 | 69 | 0.010 |
Why?
|
| Prednisone | 1 | 2002 | 258 | 0.010 |
Why?
|
| Penis | 1 | 2001 | 65 | 0.010 |
Why?
|
| CREB-Binding Protein | 1 | 2001 | 16 | 0.010 |
Why?
|
| Cadaver | 1 | 2001 | 204 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2005 | 611 | 0.010 |
Why?
|
| Anal Canal | 1 | 2001 | 92 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 380 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2001 | 87 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 1125 | 0.010 |
Why?
|
| Dinoprostone | 1 | 2001 | 74 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2001 | 133 | 0.010 |
Why?
|
| Arthritis | 1 | 2001 | 53 | 0.010 |
Why?
|
| Nocodazole | 1 | 2000 | 18 | 0.010 |
Why?
|
| Colchicine | 1 | 2000 | 23 | 0.010 |
Why?
|
| Diarrhea | 1 | 2001 | 181 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2000 | 68 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2006 | 854 | 0.010 |
Why?
|
| Rhabdomyolysis | 1 | 2000 | 28 | 0.010 |
Why?
|
| Vinblastine | 1 | 2000 | 100 | 0.010 |
Why?
|
| Vincristine | 1 | 2000 | 113 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 191 | 0.010 |
Why?
|
| Renal Insufficiency | 1 | 2000 | 99 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 1999 | 82 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2001 | 359 | 0.010 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1999 | 23 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1999 | 141 | 0.010 |
Why?
|
| CTLA-4 Antigen | 1 | 1999 | 145 | 0.010 |
Why?
|
| Guanine | 1 | 1999 | 207 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 1999 | 171 | 0.010 |
Why?
|
| Hepatitis B | 1 | 1999 | 82 | 0.010 |
Why?
|
| Genes, MHC Class II | 1 | 1998 | 31 | 0.010 |
Why?
|
| Th1 Cells | 1 | 1999 | 171 | 0.010 |
Why?
|
| Shock | 1 | 1998 | 47 | 0.010 |
Why?
|
| Th2 Cells | 1 | 1999 | 151 | 0.010 |
Why?
|
| Genes, MHC Class I | 1 | 1998 | 48 | 0.010 |
Why?
|
| Intestinal Absorption | 1 | 1998 | 126 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 1998 | 101 | 0.010 |
Why?
|
| Breast | 1 | 2000 | 297 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2000 | 498 | 0.010 |
Why?
|
| Protein Kinase C-alpha | 1 | 1998 | 29 | 0.010 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 1997 | 8 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1998 | 173 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1998 | 136 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2001 | 992 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2000 | 364 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 1997 | 83 | 0.010 |
Why?
|
| Polyploidy | 1 | 1996 | 19 | 0.010 |
Why?
|
| Diploidy | 1 | 1996 | 35 | 0.010 |
Why?
|
| Homozygote | 1 | 1996 | 208 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 1998 | 237 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1996 | 68 | 0.010 |
Why?
|
| Aneuploidy | 1 | 1996 | 64 | 0.010 |
Why?
|
| Amoxicillin | 1 | 1995 | 12 | 0.010 |
Why?
|
| Bismuth | 1 | 1995 | 8 | 0.010 |
Why?
|
| Thrombosis | 1 | 1998 | 326 | 0.010 |
Why?
|
| Metronidazole | 1 | 1995 | 26 | 0.010 |
Why?
|
| Acetaminophen | 1 | 1995 | 61 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 1996 | 238 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 1996 | 368 | 0.010 |
Why?
|
| Cell Cycle | 1 | 1996 | 518 | 0.010 |
Why?
|
| Forecasting | 1 | 1994 | 317 | 0.010 |
Why?
|